<DOC>
	<DOCNO>NCT01218568</DOCNO>
	<brief_summary>The study double blind respect rifaximin , randomization perform use table computer-generated random number . All subject follow till recovery HE ( primary end point ) 10 day whichever earlier . In Lactulose group ( group A ) patient receive 30-60 ml lactulose 2 3 divided dos patient pass 2-3 semisoft stool per day along placebo . In lactulose plus rifaximin group ( group B ) patient receive cap rifaximin 400mg three time day along lactulose . Primary endpoint recovery overt HE patient recover HE 10 day continue treatment . Total duration study 1 year .</brief_summary>
	<brief_title>Rifaximin Plus Lactulose Versus Lactulose Alone Treatment Hepatic Encephalopathy : Double Blind Randomized Trial</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Cirrhosis Age 1880 Hepatic encephalopathy grade IIIV Informed consent 1 . Degenerative CNS disease major psychiatric illness 2 . Serum creatinine &gt; 1.5 mg/dl 3 . Active alcohol intake &lt; 4 week prior present episode 4 . Others metabolic encephalopathy 5 . Hepatocellular Carcinoma 6 . Severe comorbidity CHF , Pulmonary disease , Neurological &amp; Psychiatric problem impair quality life</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>